Why tocilizumab could be an effective treatment for severe COVID-19?

A severe pneumonia-associated respiratory syndrome caused by a new coronavirus was identified in December 2019 (COVID-19), spread rapidly and has become a world-wide public health challenge. About 25% of COVID-19 patients experienced severe complications including acute respiratory distress syndrome...

Full description

Saved in:

Bibliographic Details
Published in:	Journal of translational medicine Vol. 18; no. 1; pp. 164 - 5
Main Authors:	Fu, Binqing, Xu, Xiaoling, Wei, Haiming
Format:	Journal Article
Language:	English
Published:	London BioMed Central 14.04.2020 BioMed Central Ltd Springer Nature B.V BMC
Subjects:	Acute respiratory distress syndrome (ARDS) Alveoli Antibodies, Monoclonal, Humanized - therapeutic use Autopsy Betacoronavirus Biomedical and Life Sciences Biomedicine Biopsy Care and treatment China Combination strategies Commentary Coronavirus Infections - drug therapy Coronavirus Infections - immunology Coronaviruses COVID-19 COVID-19 Drug Treatment Exploration Gas exchange Health aspects Hospital patients Humans IL-6 Immune response Immunosuppressive agents Inflammation Inflammatory storm Interleukin 6 Interleukin-6 - antagonists & inhibitors Interleukins Lymphocytes T Medical research Medicine/Public Health Middle East respiratory syndrome Monoclonal antibodies Monocytes Mortality Pandemics Patients Pneumonia, Viral - drug therapy Pneumonia, Viral - immunology Public health Respiratory diseases Respiratory distress syndrome Respiratory function SARS-CoV-2 Severity of Illness Index T cells Tocilizumab United Kingdom United Kingdom China COVID-19 SARS-CoV-2 Inflammatory storm Acute respiratory distress syndrome (ARDS) Tocilizumab IL-6
ISSN:	1479-5876, 1479-5876
Online Access:	Get full text
Tags:	Add Tag No Tags, Be the first to tag this record!

Be the first to leave a comment!